Short Interest in Terumo Corp. (OTCMKTS:TRUMY) Declines By 74.5%

Terumo Corp. (OTCMKTS:TRUMYGet Free Report) was the target of a large drop in short interest during the month of June. As of June 30th, there was short interest totaling 47,370 shares, a drop of 74.5% from the June 15th total of 185,946 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 268,986 shares, the short-interest ratio is presently 0.2 days.

Terumo Price Performance

OTCMKTS:TRUMY traded up $0.10 during trading hours on Monday, reaching $13.69. 49,040 shares of the company were exchanged, compared to its average volume of 311,445. The business has a 50 day moving average of $13.81 and a 200 day moving average of $13.61. Terumo has a 1-year low of $12.08 and a 1-year high of $19.60. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.59 and a quick ratio of 0.97. The company has a market capitalization of $20.19 billion, a P/E ratio of 22.44 and a beta of 0.68.

Terumo (OTCMKTS:TRUMYGet Free Report) last released its earnings results on Friday, May 15th. The company reported $0.11 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.11. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.84 billion. Terumo had a return on equity of 9.17% and a net margin of 12.09%. Research analysts forecast that Terumo will post 0.7 EPS for the current year.

Analysts Set New Price Targets

Separately, Zacks Research upgraded Terumo to a “hold” rating in a research report on Thursday, April 9th. Two investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, Terumo currently has a consensus rating of “Hold”.

View Our Latest Analysis on Terumo

Terumo Company Profile

(Get Free Report)

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.

Featured Stories

Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.